Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritis

Abstract Rheumatoid arthritis (RA) is associated with heart and lung dysfunction. Current therapies fail to attenuate such complications. Here, we identify formyl-peptide receptor type 2 (FPR2) as a therapeutic target to treat heart and lung dysfunction associated with inflammatory arthritis. Arthri...

Full description

Bibliographic Details

Published in:	EMBO Molecular Medicine
Main Authors:	Andreas Margraf, Jianmin Chen, Marilena Christoforou, Pol Claria-Ribas, Ayda Henriques Schneider, Chiara Cecconello, Weifeng Bu, Paul R C Imbert, Thomas D Wright, Stefan Russo, Isobel A Blacksell, Duco S Koenis, Jesmond Dalli, John A Lupisella, Nicholas R Wurtz, Ricardo A Garcia, Dianne Cooper, Lucy V Norling, Mauro Perretti
Format:	Article
Language:	English
Published:	Springer Nature 2025-04-01
Subjects:	Resolution Pharmacology Pro-resolving GPCR HFpEF Lung Injury Rheumatoid Arthritis
Online Access:	https://doi.org/10.1038/s44321-025-00227-1